Should you buy GoodRx (GDRX)?

The estimate indicates a change of +13.8% from the prior-year quarter. Over the past month, shares of GoodRx have returned +2.9% versus the Zacks S&P 500 composite's -1.6% change. Currently, GDRX carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future.

Is GoodRx Holdings a good company?

GoodRx Holdings, Inc. , which belongs to the Zacks Medical Services industry, posted revenues of $187.32 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 1.40%. This compares to year-ago revenues of $195.1 million. The company has topped consensus revenue estimates three times over the last four quarters.

Where is GDRX headquartered?

The company was founded in 2011 and is headquartered in Santa Monica, California. Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is S&P 500 Select to analyze similar companies using key performance metrics; select up to 4 stocks. GDRX does not have Company Insights